Deubiquitinase inhibitors: from evolving concepts to preclinical evaluation [0.03%]
去泛素化酶抑制剂：从概念演变到临床前评估
Gunter Maubach,Lois Hamann,Matthias Stein et al.
Gunter Maubach et al.
Deubiquitinases (DUBs) regulate substrate ubiquitination, thereby modulating signal transduction, trafficking, and proteasomal degradation. They have emerged as promising therapeutic targets owing to their involvement in a variety of pathol...
Precision targeting in prostate cancer: Mechanistic drivers and the evolving clinical pipeline [0.03%]
精准前列腺癌治疗：机制驱动因素及临床管线的演变
Pratiksha Nathe,Yogesh Singh,Pooja Ratre et al.
Pratiksha Nathe et al.
Prostate cancer (PC) is one of the most common cancers among males worldwide, and its curative treatment is challenging. This review discusses pathways-including androgen receptor signalling, prostate-specific membrane antigen, DNA damage r...
Targeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000 [0.03%]
针对ALS中TDP-43的靶向治疗：监管障碍、试验设计缺陷和CTx1000因果证据缺口
Michael A S Guth
Michael A S Guth
The therapeutic landscape for amyotrophic lateral sclerosis (ALS) has been characterized by decades of clinical trial failures, often attributed to biological heterogeneity, end-point insensitivity, and a profound evidence gap regarding tar...
Corrigendum to "Estimating the global inventory of deprioritized clinical-stage drug development programs: toward a market for shelved assets" [Drug Discov. Today 31(4) 2026 104723] [0.03%]
关于“估计临床阶段被搁置的药物研发项目的全球库存：向被搁置资产市场迈进”的勘误注释[Drug Discov. Today 31(4) 2026 104723]
Annette Bakker,Tanisha Carino,Joonhyuk Cho et al.
Annette Bakker et al.
Published Erratum
Drug discovery today. 2026 Jul 28:104747. DOI:10.1016/j.drudis.2026.104747 2026
Interplay between RNA m6A modification and transglutaminase 2 inhibitor effects on mitophagy dysfunction in Alzheimer's disease [0.03%]
m6A修饰与脂肪酶2抑制剂对阿尔茨海默病线粒体自噬障碍的互作关系研究
Ankita Chatterjee,Thakur Gurjeet Singh,Shareen Singh et al.
Ankita Chatterjee et al.
Alzheimer's disease (AD) involves amyloid-β aggregation, tau hyperphosphorylation and mitochondrial dysfunction with defective mitophagy. Emerging evidence implicates RNA N6-methyladenosine (m6A) modification and transglutaminase 2 (TG2) a...
Toward sustainable therapeutics: integrating regenerative medicine into pharmacological sustainability frameworks [0.03%]
面向可持续治疗：将再生医学整合到药理学可持续框架中
Diego Delgado,Unax Lertxundi,Laura Brizuela et al.
Diego Delgado et al.
Pharmaceutical sustainability often focuses on green manufacturing yet reducing long-term drug dependency remains overlooked. Chronic pharmacotherapy imposes a considerable clinical, economic, and environmental burden, as active pharmaceuti...
Capitalising on Regulators' Product Data Standards: What's in it For Drug Developers? [0.03%]
监管机构的产品数据标准：药物开发者的机遇与挑战
Hans van Leeuwen
Hans van Leeuwen
Jochen Baumeister,Guy Doron
Jochen Baumeister
Despite major investments in technology and artificial intelligence (AI), the pharmaceutical industry faces persistent underperformance, with clinical trial dropout rates of 30-70% and sales variability of up to 300%. Behavioral factors are...
Targeting ADAM15 in cancer: from dual-faced biology to emerging therapies [0.03%]
靶向癌症中的ADAM15：从双重生物学面向到新兴疗法
Ali El-Far,Binghui Song,Junjiang Fu et al.
Ali El-Far et al.
A disintegrin and metalloproteinase 15 (ADAM15) is a cell-surface protease with a paradoxical role in cancer development. In this review, we provide a comprehensive overview of the dual functions of ADAM15, highlighting recent mechanisms in...
Charles H Jones,Marie Beitelshees,Mikael Dolsten
Charles H Jones
Europe's ageing population is transforming universal healthcare from a financing challenge into a delivery-capacity challenge. Longer lives are increasingly accompanied by multimorbidity, polypharmacy, dementia, cardiometabolic disease, can...